Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.